Introduction
The report of unusual malformations occurring in the fetuses of women exposed to Debendox (dicyclomine hydrochloride 10 mg, doxylamine succinate 10 mg, pyridoxine hydrochloride 10 mg) early in pregnancy' prompted analysis of two prospective studies undertaken by the The English figure for other abnormal outcomes (3 2%) exceeded the Scottish figure (1 1 %) because the follow-up procedure established in the Scottish study resulted in the hardening of diagnostic criteria, with the rejection of some so-called abnormalities and sharper definition of doubtful cases. The rate for non-malformed stillbirths and neonatal deaths was 1-6% in each study. Table II shows the anatomical distribution of the defined malformations. The small differences between the two studies reflect the different follow-up arrangements.
During the first 13 weeks of pregnancy, dated from the last menstrual period, 620 of the women had been prescribed Debendox (483 in Scotland and 137 in England). Table III shows the outcome of the pregnancies. The 31 abnormal cases are listed in the Appendix, which includes the nature of the malformation and the gestational age at first prescription. There was no particular prevalence of any type of malformation.
Of the 589 women who were issued with a prescription for Debendox many practices including a total of 458 doctors (290 in Scotland, 168 in England). No assessment was made whether the patient presented the prescription for dispensing or actually took the drug. This was of little relevance, however, since non-compliance was likely to be just as prevalent among those with normal outcomes as among those with abnormal outcomes. The total use of Debendox was less in the English study than in that reported from Northern Ireland,4 where the prescribing rate for Debendox in 1966 was 11-4 prescriptions per 100 live births, rising rapidly over the next five years. An estimate of the equivalent figure based on the English data was 3 0; and, assuming the basis of this estimate applied equally in Scotland, the estimated Scottish equivalent was 5-6. Our figures were derived from women rather than prescriptions and were based on data collected in 1964 and 1965. They reflect the market penetration of Debendox in Britain in the mid-1960s. Debendox accounted for about 10% of all antiemetics prescribed. The two studies included the ascertainment of self-medication at each consultation. No instance of self-medication with Debendox was identified in a systematic examination of the original records.
If a drug causes fetal malformation it is probable that specific symptom complexes will be identified and, further, that exposure periods of increased risk will be identifiable. In these studies there was neither a concentration of specific abnormalities nor any particular concentration of exposure period among the women with abnormal outcomes. The combination of limbreduction defects and exomphalos was associated with exposure to Debendox at around the sixth week of gestation.' In this study there were two similar cases: in one the mother had received Debendox on the 56th day after the last menstrual period and penicillin for an upper respiratory illness one week before. The other mother had not received any drugs in early pregnancy.
We conclude that Debendox is not specifically incriminated as a cause of fetal malformation. Although there were 31 (table I) . In 20 cases the onset of the disease occurred during September to December (table II) . The affected joints were knees (19 instances); ankles (12); fingers (15); wrists (nine); toes (nine); shoulders (four); elbows (four); and low back (four). Over four joints were affected in 13 patients. The acute joint symptoms lasted from six weeks to 12 months.
FOLLOW-UP INVESTIGATION
Of the six patients who were free of joint symptoms and had normal physical findings, one (case 27) developed an atrioventricular conduction block, probably after yersinia myocarditis. In the remaining 25 patients joint complaints and findings varied (table I) . A
